Interleukin-6
Olokizumab plus methotrexate safe, efficacious through 106 weeks in rheumatoid arthritis
Olokizumab combined with methotrexate for the treatment of rheumatoid arthritis maintains its safety and efficacy profile through 106 weeks, according to data published in Annals of the Rheumatic Diseases.
FDA approves Kevzara for polyarticular juvenile idiopathic arthritis
The FDA has approved the interleukin-6 inhibitor Kevzara for the treatment of polyarticular juvenile idiopathic arthritis, according to a press release from Regeneron Pharmaceuticals and Sanofi.
VIDEO: 'Exciting time' for therapeutic options in polymyalgia rheumatica
In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.
Targeting IL-6 can help rheumatologists, patients ‘seek shelter from the cytokine storm’
Targeting interleukin-6 can help rheumatologists manage severe, high-grade inflammation including cytokine storm, according to a presenter at the 2023 AWIR annual conference.
Biologic DMARDs control ICI-associated inflammatory arthritis quicker than methotrexate
Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.
Olokizumab effective in patients with rheumatoid arthritis unresponsive to TNF inhibitors
In patients with rheumatoid arthritis who failed to respond to TNF inhibitors, olokizumab is effective and carries an acceptable safety risk, especially when paired with methotrexate, according to data published in Clinical Rheumatology.
EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis
Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.
IL-1 inhibitors linked to ‘significant reduction’ in COVID-19 mortality
Interleukin-1 inhibitors are associated with a “significant reduction” in mortality among patients hospitalized with COVID-19, respiratory insufficiency and hyperinflammation, according to data published in The Lancet Rheumatology.